NXT-ID, Inc., (OTCQB: NXTD) a biometrics company focused on the growing m-commerce market, announces that Gino Pereira, Chief Executive Officer of NXT-ID, Inc. will be presenting additional images and a live product presentation of the Wocket™ March 11th in an all-day conference at the New York Hilton Midtown. Video coverage will also be available online following the presentation for interested media and shareholders.… Read more
Stem Cell Therapeutics Corp. (TSX VENTURE:SSS)(SCTPF), an immuno-oncology company developing cancer stem cell-related therapeutics, today announced that Mr. Luke Beshar and Dr. Thomas Reynolds have been appointed to the Company’s Board of Directors.
Luke Beshar is Executive Vice President and Chief Financial Officer of NPS Pharmaceuticals. He joined the company in 2007 and has been responsible for financial management, … Read more
Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,658,627 entitled, Pregnancy Hormone Combination for Treatment of Autoimmune Diseases, to the Regents of the University of California (UCLA). The patent includes claims to the use of … Read more
Keryx Biopharmaceuticals, Inc. (KERX) (the “Company”) today announced it has submitted a Marketing Authorization Application (“MAA”) to the European Medicines Agency (“EMA”), seeking the approval of Zerenex(TM) (ferric citrate coordination complex) as a treatment for hyperphosphatemia in patients with chronic kidney disease (“CKD”), including dialysis- and non-dialysis dependent CKD.
The MAA will be reviewed by the EMA Committee for Medicinal Products … Read more
Progress update and strategy insight for year ahead
Highlights of the letter include:
- Discussion of growth catalysts for 2014
- A review of milestones in 2013
- Timing update on delivery of redesigned down hole tools
- Discussion of financial strategy for 2014
March 10th, 2014
Dear Propell Technologies Shareholders:
To begin I want to extend my gratitude … Read more
SurePure, Inc. (SURP) a global leader in liquid photopurification, today announced that it has sold its unique processing technology to Soda King (www.sodaking.co.za), a leading South African beverage producer. SurePure’s announcement follows its sale on February 2014 of its patented photopurification technology to a French flavor house.
Soda King has bought the technology to help preserve its flavors for … Read more
Regenerative medicine company Mesoblast Limited (ASX:MSB; USOTC:MBLTY) today announced that William M. Burns, former Chief Executive Officer of Roche Pharmaceuticals, has been appointed a non-executive Director of the Mesoblast Board, effective immediately.
Mr Burns was the CEO of the pharmaceutical division of Swiss global healthcare company F.Hoffman La Roche (Roche) from 2005-2009, and a non-executive member of the Roche Board … Read more
NeoStem, Inc. (NBS) (“NeoStem” or the “Company”), a leader in the emerging cellular therapy industry, announced today that it has entered into a sponsored research collaboration with Massachusetts Eye and Ear/Schepens Eye Research Institute, an affiliate of Harvard Medical School.
In this collaboration, NeoStem will sponsor research in the laboratory of principal investigator Michael Young, Ph.D., Director of the Ocular Regenerative Medicine Institute … Read more
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN:US74154B2034) (“Prima,” “the Company”) is pleased to advise that it has received approximately $1.6 million in cash rebate from the Australian federal government’s R&D tax incentive program. The cash rebate was provided essentially in respect of expenditure incurred on eligible Australian R&D activities conducted on the CVac clinical trials during the 2013 financial year.
About Prima BioMed
Prima … Read more
Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (“Prima,” “the Company”) will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.
Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Maxim Group and Piper Jaffray, this one-day investor conference focuses exclusively on the regenerative medicine and advanced therapies sector. … Read more